LONG-TERM ASSESSMENT OF EFGARTIGIMOD IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS: ADAPT+ STUDY INTERIM RESULTS

Authors
Category Primary study
JournalJournal of Neurology, Neurosurgery and Psychiatry
Year 2022
This article has no abstract
Epistemonikos ID: 0e8cccb3b8171f882700afc29a11e724f49649ab
First added on: Feb 15, 2025